The KDIGO Clinical Practice Guideline 2022 for the management of diabetes in chronic kidney disease now includes SGLT-2 inhibitors in addition to metformin, ACE/ARB, and statin as a first-line treatment for T2DM. This evidence concerns the gene SLC5A2 and diabetes mellitus.